Psilocybin for Treatment-Resistant OCD: A Randomised Controlled Trial
SSRN Electronic Journal 2026 Ben Kelemndi, Thomas G. Adams, Terence H. W. Ching et al. 1 citation preprint
Background: Obsessive-compulsive disorder (OCD) affects 2–3% of the population worldwide, and 40–60% of patients do not respond to first-line treatments. We evaluated the efficacy and safety of a single dose of psilocybin in adults with treatment-resistant OCD.Methods: In this phase 2, randomised, double-blind, placebo-controlled trial at the Connecticut Mental Health Center, Yale University...
DOI: 10.2139/ssrn.6218466 (opens in new tab)
Psilocybin
Adverse effect
Randomized controlled trial
Population
+4